Association of clinical parameters and overall survival (OS) in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with high-dose interleukin-2 (HD IL-2)

被引：0
|
作者：
Stenehjem, David D.
Parikh, Kinjal
Batten, Julia Anne
Van Atta, Joan
Crispin, Hilda
Sageser, Daniel S.
Grossmann, Kenneth F.
Wang, Junfeng
Tantravahi, Srinivas Kiran
Samlowski, Wolfram E.
Agarwal, Neeraj
机构：
[1] Univ Utah, Coll Pharm, Pharmacotherapy Outcomes Res Ctr, Salt Lake City, UT 84112 USA
[2] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[3] Comprehens Canc Ctr Nevada, Las Vegas, NV USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 04期
关键词：
D O I：
10.1200/jco.2014.32.4_suppl.476
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
476
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Long-term disease- free survival (DFS) of metastatic melanoma (mM) and renal cell cancer (mRCC) patients following high-dose interleukin-2 (HD IL2)
    Clark, Joseph
    Curti, Brendan
    Davis, Elizabeth
    Kaufman, Howard
    Amin, Asim
    Alva, Ajjai
    Logan, Theodore
    Hauke, Ralph
    Miletello, Gerald
    Vaishampayan, Ulka
    Johnson, Douglas
    White, Richard
    Wiernik, Peter
    Dutcher, Janice
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [42] Maintenance interleukin-2 (IL-2) and sargramostim (GM-CSF) following high-dose IL-2 (HD IL-2) therapy for metastatic melanoma
    Chu, Melinda Bernabe
    Fesler, Mark
    Armbrecht, Eric
    Fosko, Scott
    Hsueh, Eddy C.
    Richart, John M.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [43] Phase 2 Trial of High-Dose Interleukin-2 (IL-2) and Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Clear Cell Renal Cell Carcinoma (mRCC)-Interim Analysis of i-SAbR IL-2 Trial
    Ishihara, D.
    Louder, K.
    Akter, M.
    Ahn, C.
    Margulis, V.
    Arriaga, Y.
    Courtney, K.
    Timmerman, R. D.
    Brugarolas, J.
    Hannan, R.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : S96 - S97
  • [44] Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma
    Ajjai Alva
    Gregory A. Daniels
    Michael K. K. Wong
    Howard L. Kaufman
    Michael A. Morse
    David F. McDermott
    Joseph I. Clark
    Sanjiv S. Agarwala
    Gerald Miletello
    Theodore F. Logan
    Ralph J. Hauke
    Brendan Curti
    John M. Kirkwood
    Rene Gonzalez
    Asim Amin
    Mayer Fishman
    Neeraj Agarwal
    James N. Lowder
    Hong Hua
    Sandra Aung
    Janice P. Dutcher
    Cancer Immunology, Immunotherapy, 2016, 65 : 1533 - 1544
  • [45] Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma
    Alva, Ajjai
    Daniels, Gregory A.
    Wong, Michael K. K.
    Kaufman, Howard L.
    Morse, Michael A.
    McDermott, David F.
    Clark, Joseph I.
    Agarwala, Sanjiv S.
    Miletello, Gerald
    Logan, Theodore F.
    Hauke, Ralph J.
    Curti, Brendan
    Kirkwood, John M.
    Gonzalez, Rene
    Amin, Asim
    Fishman, Mayer
    Agarwal, Neeraj
    Lowder, James N.
    Hua, Hong
    Aung, Sandra
    Dutcher, Janice P.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2016, 65 (12) : 1533 - 1544
  • [46] High-dose interleukin-2 immunotherapy is safe for patients with metastatic renal cell carcinoma on dialysis
    Brusky, JP
    Gailani, F
    Pathak, A
    Patel, H
    Aboseif, S
    BJU INTERNATIONAL, 2006, 97 (02) : 279 - 280
  • [47] Can outpatient interleukin-2 and interferon replace high-dose interleukin-2 for metastatic renal cell carcinoma?
    Johannes Vieweg
    Nature Clinical Practice Oncology, 2005, 2 : 192 - 193
  • [48] Can outpatient interleukin-2 and interferon replace high-dose interleukin-2 for metastatic renal cell carcinoma?
    Vieweg, J
    NATURE CLINICAL PRACTICE ONCOLOGY, 2005, 2 (04): : 192 - 193
  • [49] High-dose (HD) IL-2 for metastatic renal cell carcinoma (mRCC) in the targeted therapy era: Extension of OS benefits beyond complete response (CR) and partial response (PR).
    Morse, Michael
    McDermott, David F.
    Daniels, Gregory A.
    Kaufman, Howard
    Wong, Michael K. K.
    Aung, Sandra
    Lowder, James N.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [50] A retrospective analysis of high-dose aldesleukin (HD IL-2) following immune checkpoint blockade (ICB) in metastatic melanoma (MM) and metastatic renal cell carcinoma (mRCC).
    Gunturi, Anasuya
    Aung, Sandra
    McDermott, David F.
    Buchbinder, Elizabeth Iannotti
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345